摘要
目的 :研究多个耐药基因P -糖蛋白(P gp)、谷胱甘肽S -转移酶 (GST π)、DNA拓扑异构酶 -Ⅱ (Topo Ⅱ )在卵巢癌组织中表达 ,探讨其在卵巢癌化学治疗耐药中的作用及与临床病理学特征间的关系。方法 :应用免疫组化SP法对 3 7例卵巢癌、10例卵巢良性肿瘤和 8例正常卵巢组织中P gp、GST π和Topo Ⅱ表达状况进行测定。结果 :P gp、GST π和Topo Ⅱ在卵巢癌组织中阳性表达均高于良性肿瘤和正常组织对照组 ,P<0 0 5。P gp表达与卵巢癌组织类型、分化程度、临床分期均无关 ,P >0 0 5。GST π表达与肿瘤分化程度显著相关 ,P <0 0 1;与卵巢癌组织类型无关 ,P >0 0 5。Ⅲ、Ⅳ期组织中GST π阳性表达率显著高于Ⅰ、Ⅱ期( 91 3 %vs 5 7 1% ) ,P <0 0 5。Topo Ⅱ表达仅与肿瘤分化程度有关 ,P <0 0 5 ,而与组织类型和临床分期均无关 ,P >0 0 5。三者在卵巢癌组织中存在共同表达。结论 :卵巢癌存在原发性耐药并涉及多个耐药基因的共同表达。
OBJECTIVE: To investigate the clinical significance of the expressions of P-gp,GST-π and Topo-Ⅱ in ovarian carcinoma tissues and evaluate their roles in chemoresistance of ovarian carcinoma .METHODS: The expressions of P-gp,GST-π and Topo-Ⅱ in 37 cases of ovarian carcinoma,10 benign ovarian tumors and 8 normal controls were determined by using SP immunohistochemical technique,and the results were analysed in correlation with some clinical and pathological data.All the patients had not received chemothereapy before operation. RESULTS:The positive expressions of P-gp,GST-π and Topo-Ⅱ in patients with ovarian carcinoma were all higher than those in benign tumors and normal controls,P<0.05.A significant correlation was shown between GST-π and differentiated degree,P<0.01,and clinical stages(91.3% vs 57.1%),P<0.05. The expression level of Topo-Ⅱ was associated with differentiated degree,P<0.05.No significant differences with the expression of P-gp were found in relation to the histopathology,differentiated degree and clinical stage ,P>0.05. CONCLUSIONS:Primary multidrug resistance really exists in ovarian carinoma.Multiple gene co-expression is also involved in drugresistance in ovarian carcinoma.Combined determination of P-gp ,GST-π and Topo-Ⅱmay be useful for predicting the chemosensitivities and chemoresponsiveness of ovarian carcinoma.
出处
《肿瘤防治杂志》
2004年第5期512-514,共3页
China Journal of Cancer Prevention and Treatment
基金
扬州市卫生局科研课题基金资助 ( 2 0 0 0 15 )
